Al-Saedy Miriam, Al-Saedy Salsabeal, Robinson David
Internal Medicine, Virginia Mason Medical Center, Seattle, USA.
Medicine, Elson S. Floyd College of Medicine, Spokane, USA.
Cureus. 2025 Apr 2;17(4):e81624. doi: 10.7759/cureus.81624. eCollection 2025 Apr.
We present the case of a 44-year-old woman with a history of chronic idiopathic urticaria (CIU) who initially achieved remission with omalizumab (Xolair) but experienced a relapse following a hysterectomy. Despite reinitiating treatment, her symptoms persisted, requiring escalating doses of antihistamines and systemic corticosteroids. This case highlights the potential role of hormonal shifts and surgical stress in triggering urticaria recurrence and contributing to biologic treatment failure, though causality remains unproven due to the lack of objective hormonal or immunologic data. It underscores the importance of closely monitoring treatment response over time and exploring alternative therapeutic strategies when standard approaches prove inadequate. Further research is needed to elucidate the mechanisms underlying post-surgical urticaria exacerbations and optimize long-term management for affected patients.
我们报告了一例44岁患有慢性特发性荨麻疹(CIU)的女性病例。该患者最初使用奥马珠单抗(Xolair)实现了缓解,但在子宫切除术后病情复发。尽管重新开始治疗,她的症状仍持续存在,需要增加抗组胺药和全身性糖皮质激素的剂量。该病例突出了激素变化和手术应激在触发荨麻疹复发及导致生物治疗失败方面的潜在作用,不过由于缺乏客观的激素或免疫学数据,因果关系尚未得到证实。这强调了随着时间推移密切监测治疗反应以及在标准方法证明不足时探索替代治疗策略的重要性。需要进一步研究以阐明术后荨麻疹加重的潜在机制,并优化对受影响患者的长期管理。